The European Respiratory Journal targets tuberculosis

European Respiratory Journal

Volumn 36, Issue 4, 2010, Pages 714-715

  Lange, C ^a   Yew, W W ^b   Migliori, G B ^c   Raviglione, M ^c  

^a RESEARCH CENTER BORSTEL   (Germany)

^b GRANTHAM HOSPITAL   (Hong Kong)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GATIFLOXACIN; ISONIAZID; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

BACTERIUM CULTURE; DISEASE CONTROL; DISEASE TRANSMISSION; EDITORIAL; HEALTH PROGRAM; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS; VACCINATION;

COMMUNICABLE DISEASE CONTROL; EUROPE; HUMANS; PERIODICALS AS TOPIC; PULMONARY MEDICINE; RISK; TUBERCULOSIS;

EID: 77957845230     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00055310     Document Type: Editorial

References (16)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO Report 2009. World Health Organization Document: WHO/HTM/TM2009.4111-303.
2. World Health Organization. Global tuberculosis control: a short update to the 2009 report. World Health Organization Document: WHO/HTM/TB2009.4261-48.
3. World Health Organization. Fact Sheet: Top ten causes of deaths. World Health Organization Document, 2008. www.who.int/mediacentre/factsheets/fs310/en/ index.html Date last updated: October 2008. Date last accessed: April 2010.
4. Dye C, Maher D, Weil D, et al. Targets for global tuberculosis control. Int J Tuberc Lung Dis 2006; 10: 460-462.
5. Uplekar M, Pathania V, Raviglione M. Private practitioners, public health, weak links in tuberculosis control. Lancet 2001; 358: 912-916. (Pubitemid 32900580)
6. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB). 2010 Global report on surveillance and response. WHO, Geneva, 2010. World Health Organization Document WHO/HTM/TB2010.31-71.
7. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 1: CD000171.
8. Lange C, Mori T. Advances in the diagnosis of tuberculosis, Respirology 2010; 15: 220-240.
9. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-1170. (Pubitemid 351717577)
10. Lange C, Pai M, Drobniewski F, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis sensible or silly? Eur Respir J 2009; 33: 1250-1253.
11. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType(R) MTBDRplus. Assay for rifampicin, isoniazid susceptibility testing of Mycobacterium tuberculosis strains and in clinical specimens. J Clin Microbiol 2007; 45: 2635-2640. (Pubitemid 47295497)
12. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinoloneamikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-1772.
13. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment or pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
14. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
15. Migliori GB, Loddenkemper R, Blasi F, et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
16. Erkens CGM, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010; 36: 925-949.